Volume 21 Issue 2
Feb.  2023
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2023  >  21(2): 337-340
CAI Hui-long, YUAN Wei-guang, AN Jing, LIN Jing, GUO Jing-jie, DONG Yuan-di, LIU Bao, SUN Hui-xin. Disease burden and risk factors of pancreatic cancer in China in 1990 and 2019[J]. Chinese Journal of General Practice, 2023, 21(2): 337-340. doi: 10.16766/j.cnki.issn.1674-4152.002877
Citation: CAI Hui-long, YUAN Wei-guang, AN Jing, LIN Jing, GUO Jing-jie, DONG Yuan-di, LIU Bao, SUN Hui-xin. Disease burden and risk factors of pancreatic cancer in China in 1990 and 2019[J]. Chinese Journal of General Practice, 2023, 21(2): 337-340. doi: 10.16766/j.cnki.issn.1674-4152.002877
shu

Disease burden and risk factors of pancreatic cancer in China in 1990 and 2019

doi: 10.16766/j.cnki.issn.1674-4152.002877
  • 1.

    Institute of Cancer Prevention and Treatment, Harbin Medical University, Harbin, Heilongjiang 150081, China

Funds:

 YQ2021H021

  • Received Date: 2022-01-06
    Available Online: 2023-04-20
    Abstract
  •   Objective  To analyse the incidence, mortality and disease burden of pancreatic cancer in China in 1990 and 2019.  Methods  The global disease burden database in 2019 was used to analyse the incidence, mortality, disability adjusted life years (DALY), premature death loss years (YLL) and disability life years (YLD) of pancreatic cancer in the total population and age groups in 1990 and 2019. Risk factors attributable to pancreatic cancer were also analysed.  Results  The incidence of pancreatic cancer in China was 114 900 in 2019, and the incidence rate was 8.08/105, representing an increase of 330.34% and 257.52% compared with 1990. In 2019, the number of deaths was 117 400, and the mortality rate was 8.25/105, indicating an increase of 333.21% and 260.26% compared with 1990. In 2019, the DALY, YLD and YLL of pancreatic cancer in China were 2 805 200, 23 900 and 2 781 300, by contrast, form 1990, such values increased by 274.33%, 319.30% and 273.98%, respectively. In 2019, the incidence rate, mortality rate and DALY rate of pancreatic cancer increased with age. The highest incidence rate (44.75/105), mortality rate (50.09/105) and DALY rate (742.81/105) were all observed in the >70 age group. The mortality rate, DALY and YLL attributed to smoking in Chinese patients with pancreatic cancer was 26 552, 612 359 and 607 033, respectively.  Conclusion  The burden of pancreatic cancer in China has increased considerably from 1990 to 2019. Therefore, positive preventive measures should be taken to reduce the burden of pancreatic cancer.

     

    • FullText(HTML)
  • loading
    • References(18)
  • [1]
    SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
    [2]
    MAISONNEUVE P. Epidemiology and burden of pancreatic cancer[J]. Presse Med, 2019, 48(3 Pt 2): e113-e123. http://www.onacademic.com/detail/journal_1000042279459099_c05f.html
    [3]
    杨军, 李贺, 郑荣寿, 等. 2014年中国胰腺癌发病与死亡分析[J]. 中国肿瘤, 2018, 27(6): 420-425. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201806005.htm

    YANG J, LI H, ZHENG R S, et al. Incidence and mortality of pancreatic cancer in China, 2014[J]. China Cancer, 2018, 27(6): 420-425. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201806005.htm
    [4]
    GBD 2017 Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990—2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet Gastroenterol Hepatol, 2019, 4(12): 934-947. doi: 10.1016/S2468-1253(19)30347-4
    [5]
    KLEIN A P. Pancreatic cancer: a growing burden[J]. Lancet Gastroenterol Hepatol, 2019, 4(12): 895-896. doi: 10.1016/S2468-1253(19)30323-1
    [6]
    王亮亮, 丁高恒, 陈莉莉, 等. 2009—2015年甘肃省肿瘤登记地区胰腺癌流行特征及变化趋势分析[J]. 实用肿瘤学杂志, 2021, 35(3): 200-206. https://www.cnki.com.cn/Article/CJFDTOTAL-SYZL202103002.htm

    WANG L L, DING G H, CHEN L L, et al. Trends of incidence and mortality of pancreatic cancer in Gansu cancer registration areas, 2009—2015[J]. Journal of Practical Oncology, 2021, 35(3): 200-206. https://www.cnki.com.cn/Article/CJFDTOTAL-SYZL202103002.htm
    [7]
    LIN Q J, YANG F, JIN C, et al. Current status and progress of pancreatic cancer in China[J]. World J Gastroenterol, 2015, 21(26): 7988-8003. doi: 10.3748/wjg.v21.i26.7988
    [8]
    MCGUIGAN A, KELLY P, TURKINGTON R C, et al. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes[J]. World J Gastroenterol, 2018, 24(43): 4846-4861. doi: 10.3748/wjg.v24.i43.4846
    [9]
    MASOUDI S, MOMAYEZ SANAT Z, MAHMUD SALEH A, et al. Menstrual and reproductive factors and risk of pancreatic cancer in women[J]. Middle East J Dig Dis, 2017, 9(3): 146-149. doi: 10.15171/mejdd.2017.65
    [10]
    韦筱燕, 张家强, 沙莎. 老年人营养风险指数对胰十二指肠切除术患者术后并发症的预测价值[J]. 中华全科医学, 2021, 19(2): 176-178, 231. doi: 10.16766/j.cnki.issn.1674-4152.001760

    WEI X Y, ZHANG J Q, SHA S. The predictive value of nutritional risk index in elderly patients with postoperative complications after pancreatoduodenectomy[J]. Chinese Journal of General Practice, 2021, 19(2): 176-178, 231. doi: 10.16766/j.cnki.issn.1674-4152.001760
    [11]
    MIDHA S, CHAWLA S, GARG P K, et al. Modifiable and non-modifiable risk factors for pancreatic cancer: a review[J]. Cancer Lett, 2016, 381(1): 269-277. doi: 10.1016/j.canlet.2016.07.022
    [12]
    YU J, BLACKFORD A L, MOLIN M D, et al. Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages[J]. Gut, 2015, 64(11): 1783-1789. doi: 10.1136/gutjnl-2014-308653
    [13]
    PEREIRA S P, OLDFIELD L, NEY A, et al. Early detection of pancreatic cancer[J]. Lancet Gastroenterol Hepatol, 2020, 5(7): 698-710. doi: 10.1016/S2468-1253(19)30416-9
    [14]
    BARTOLI M, BARAT M, DOHAN A, et al. CT and MRI of pancreatic tumors: an update in the era of radiomics[J]. Jpn J Radiol, 2020, 38(12): 1111-1124. doi: 10.1007/s11604-020-01057-6
    [15]
    LOWENFELS A B, MAISONNEUVE P. Epidemiology and prevention of pancreatic cancer[J]. Jpn J Clin Oncol, 2004, 34(5): 238-244. doi: 10.1093/jjco/hyh045
    [16]
    ANSARY-MOGHADDAM A, HUXLEY R, BARZI F, et al. The effect of modifiable risk factors on pancreatic cancer mortality in population of the Asia-Pacific region[J]. Cancer E Pidemiol Biomarkers Prev, 2006, 15(12): 2435-2440.
    [17]
    YEO T P. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma[J]. Semin Oncol, 2015, 42(1): 8-18.
    [18]
    孙惠昕, 陈王洋, 宋冰冰. 黑龙江省2013—2014年度城市癌症筛查分析[J]. 实用肿瘤学杂志, 2015, 29(4): 315-318.

    SUN H X, CHEN W Y, SONG B B. Analysis of cancer screening of 2013-2014 in Heilongjiang province[J]. Journal of Practical Oncology, 2015, 29(4): 315-318.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (484) PDF downloads(19) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return